Vol. 9 | No. 17-18, 2024


DOSIMETRIC COMPARISON OF THREE DIFFERENT EXTERNAL BEAM PARTICLES USING TREATMENT PLANNING SYSTEM MATRAD

Nermine MURADI, Gazmend NAFEZI, Fadil AJREDINI, Bashkim ZIBERI

Abstract

In recent decades, valuable clinical experience in particle therapy has been gained worldwide. Along with the development of new technologies, especially for the application of radiation and technologies related to treatment planning, every day there is a wider use of heavy particle and ion radiotherapy in clinical settings to make optimal use of physical and biological properties of protons and heavy ions. Dose confirmation is called the possibility to concentrate the radiation dose to the tumor while sparing the surrounding normal tissue, which is the aim of radiotherapy. Before the irradiation of each patient, different complex models for treatment planning are used in Radiotherapy. One of these systems is mated, an open-source TPS - Treatment Planning System based on Matlab programming language where optimal plans are calculated in advance, following the prescribed dose to cover tumor volume, while keeping constraints to limit dose for the irradiation of Organs at risk – healthy cells. The software has a dual education and research purpose with the possibility to create treatment plans, calculate and optimize doses for different modalities as for photons, protons and carbon ions. In this work, different treatment plans are created for the TG119 phantom and an exemplary prostate patient case with two beams in the optimal angles of 90° and 270°. The treatment plans are compared for three different modalities of radiation: photons, protons, and carbon ions. The goal was to minimize the dose to healthy cells while delivering 50 Gy to the TG119 case target, and 68 Gy to the target on the prostate case in 30 fractions. From the present study has been concluded that the main advantage of proton and carbon ions compared to photons is the reduction of the integral dose in healthy tissues and the delivery of a higher dose in the tumor side.

Pages: 466 - 477

DOI: https://doi.org/10.62792/ut.jnsm.v9.i17-18.p2843